-

New Herbicide Provides Exceptional Grass and Broadleaf Weed Control

Innovative combination from Bayer helps wheat growers tackle wild oat, other problem weeds

ST. LOUIS--(BUSINESS WIRE)--LuxxurTM herbicide from Bayer is now available to cereals growers in Colorado, Idaho, Minnesota, North Dakota, Oregon, South Dakota, Washington, and Wyoming for the 2020 growing season. Classified as a Group 2 herbicide, Luxxur herbicide is formulated with a precise combination of active ingredients optimized to control many grass and broadleaf weeds in spring, winter and durum wheat fields.

“Luxxur herbicide provides exceptional control of Group 1 resistant grasses, such as green foxtails, yellow foxtails and wild oats,” said Matt Smith, customer business advisor at Bayer. “It also works well for controlling Canada thistle and narrow-leaved hawksbeard, which are two especially problematic weeds for growers.”

“In trials, we’ve been pretty impressed with how well the weeds were controlled with Luxxur herbicide, even in drier conditions where the crop doesn’t canopy well,” said Carrie Pederson, northwest sales representative at Bayer. “We’re seeing excellent weed control.”

In addition to exceptional weed control, Luxxur offers rotational flexibility, season after season.

“One of the main draws with Luxxur herbicide, is the fact that farmers can rotate back to sensitive pulse crops, such as lentils in the following season,” said Pederson.

Growers can use Luxxur herbicide safely on all wheat. For optimal weed control, apply Luxxur herbicide between emergence and jointing. To maximize crop safety, growers should apply Luxxur herbicide before jointing. Spraying early helps growers maximize efficacy, tackling early emerging perennial and winter annual broadleaf weeds to help ensure a clean field.

“I’m excited because Luxxur herbicide gives growers another option for managing weeds,” said Smith. “Problems with weeds can grow exponentially, year after year. Luxxur herbicide is a new tool we have to combat those specific weeds cereals growers are dealing with.”

“Some of our grass species are becoming more tolerant to glyphosate, so we have to constantly figure out other ways to mix it up and keep mother nature guessing,” said Pederson. “To minimize herbicide resistance development, I would recommend growers adopt a durum or spring wheat rotation with lentils and Luxxur herbicide is a really good fit there.”

For the 2020 growing season, Luxxur herbicide will be available in 80-acre cases. In addition, Luxxur herbicide is included as a herbicide in Bayer PLUS Rewards. To view potential rebates on Luxxur herbicide in combination with other Bayer products, use the calculator at www.bayerplus.us.

To learn more about Luxxur herbicide and the weeds you can control using it, contact your local Bayer Cereal Expert or visit www.luxxur.us.

Bayer is committed to bringing new technology and solutions for agriculture and non-agricultural uses. For questions concerning the availability and use of products, contact a local Bayer representative, or visit Crop Science, a division of Bayer, online at www.cropscience.bayer.us.

Visit the Bayer Connect - Social Hub for social media, recent news, blog posts, videos and more from Crop Science, a division of Bayer.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros. For more information, go to www.bayer.us.

Find more information at www.cropscience.bayer.us.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

©2020 Bayer Group. Always read and follow label instructions. Bayer (reg’d), the Bayer Cross (reg’d) and Luxxur™ are trademarks of Bayer Group. Luxxur is not registered in all states. For additional product information please call toll-free 1-866-99-BAYER (1-866-992-2937) or visit our website at www.CropScience.Bayer.us. Bayer CropScience LP, 800 North Lindbergh Blvd. St. Louis, MO 63167.

Contacts

Bayer Media Hotline, 1-862-404-5118, or

Kevin Cencula
Crop Science, a division of Bayer
Tel: (919) 698-6516
Email: kevin.cencula@bayer.com

Erica Ballmer
Rhea + Kaiser
Tel: (630) 955-2514
Email: eballmer@rkconnect.com

Bayer


Release Versions

Contacts

Bayer Media Hotline, 1-862-404-5118, or

Kevin Cencula
Crop Science, a division of Bayer
Tel: (919) 698-6516
Email: kevin.cencula@bayer.com

Erica Ballmer
Rhea + Kaiser
Tel: (630) 955-2514
Email: eballmer@rkconnect.com

More News From Bayer

KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--The Phase III study FIND-CKD (NCT05047263) — investigating the efficacy and safety of KERENDIA® (finerenone) versus placebo when added to standard of care in adult patients with non-diabetic chronic kidney disease (CKD) — has met its primary endpoint.1 The results demonstrated a statistically significant improvement versus placebo in the primary efficacy outcome of estimated glomerular filtration rate (eGFR) slope, defined as the mean annual rate of change from...

Missouri Court Grants Preliminary Approval of Roundup™ Class Settlement to Resolve Current and Future Claims

ST. LOUIS--(BUSINESS WIRE)--Today, a judge in the Circuit Court of the City of St. Louis, Missouri granted preliminary approval of a class action settlement to resolve current and potential future Roundup claims alleging non-Hodgkin lymphoma (NHL) injuries. The motion was filed by leading plaintiff law firms representing the class. “We are pleased the Court granted preliminary approval of the class settlement, which is designed to resolve current and potential future Roundup claims relating to...

New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. This updated clearance expands MRXperion’s labeled field strength compatibility to support magnetic resonance imaging (MRI) scanners with magnetic...
Back to Newsroom